Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Y.S.P. Southeast Asia Holding BhdXKLS:7178 +2.46%75 ROC (Joel Greenblatt) % is 18.50% as of Mar. 2026, which is 40% above its 10-year median of 13.18. GuruFocus rates XKLS:7178 with a GF Score™ of 75/100 and a GF Value™ of RM2.41 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 982 Drug Manufacturers companies, Y.S.P. Southeast Asia Holding Bhd ranks better than 51.63% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Y.S.P. Southeast Asia Holding Bhd's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 18.50%.
The historical rank and industry rank for Y.S.P. Southeast Asia Holding Bhd's ROC (Joel Greenblatt) % or its related term are showing as below:
XKLS:7178'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 8.38 Med: 13.18 Max: 18.76
Current: 12.34
During the past 13 years, Y.S.P. Southeast Asia Holding Bhd's highest ROC (Joel Greenblatt) % was 18.76%. The lowest was 8.38%. And the median was 13.18%.
XKLS:7178's ROC (Joel Greenblatt) % is ranked better than 51.63% of 982
companies
in the Drug Manufacturers industry
Industry Median: 11.405
vs XKLS:7178: 12.34
Y.S.P. Southeast Asia Holding Bhd (XKLS:7178) ROC (Joel Greenblatt) % Explanation
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Y.S.P. Southeast Asia Holding Bhd ROC (Joel Greenblatt) % Chart
XKLS:7178 vs ZTS, UTHR, VTRS: ROC (Joel Greenblatt) % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Y.S.P. Southeast Asia Holding Bhd's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Y.S.P. Southeast Asia Holding Bhd ROC (Joel Greenblatt) % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Y.S.P. Southeast Asia Holding Bhd's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Y.S.P. Southeast Asia Holding Bhd's ROC (Joel Greenblatt) % falls into.
Y.S.P. Southeast Asia Holding Bhd ROC (Joel Greenblatt) % Calculation
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 18.50% mean?
Y.S.P. Southeast Asia Holding Bhd (XKLS:7178) has a ROC (Joel Greenblatt) % of 18.50% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Y.S.P. Southeast Asia Holding Bhd and its competitors. This is 40% above median its historical median of 13.18. Over the past decade, Y.S.P. Southeast Asia Holding Bhd's ROC (Joel Greenblatt) % has ranged from 8.38 to 18.76. According to the industry distribution chart, Y.S.P. Southeast Asia Holding Bhd ranks #475 out of 982 companies in the Drug Manufacturers industry, placing it in the top 48.4%.
Is Y.S.P. Southeast Asia Holding Bhd's ROC (Joel Greenblatt) % too high?
Y.S.P. Southeast Asia Holding Bhd's current ROC (Joel Greenblatt) % of 18.50% is 40% above median its 10-year median of 13.18. Over the past 10 years, this metric has ranged from a low of 8.38 to a high of 18.76. The Drug Manufacturers industry median ROC (Joel Greenblatt) % is 11.41. Y.S.P. Southeast Asia Holding Bhd's value of 18.50% is 62.2% above this industry median. Based on the distribution chart, Y.S.P. Southeast Asia Holding Bhd ranks #475 out of 982 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Y.S.P. Southeast Asia Holding Bhd has a GF Score™ of 75/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Y.S.P. Southeast Asia Holding Bhd's ROC (Joel Greenblatt) % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Y.S.P. Southeast Asia Holding Bhd ranks #475 out of 982 companies for ROC (Joel Greenblatt) %. This puts Y.S.P. Southeast Asia Holding Bhd in the upper half of its industry. The industry median ROC (Joel Greenblatt) % is 11.41. Y.S.P. Southeast Asia Holding Bhd's value of 18.50% is 62.2% above this benchmark. Historically, Y.S.P. Southeast Asia Holding Bhd's own ROC (Joel Greenblatt) % has ranged from 8.38 to 18.76 over the past decade. While the company's 10-year median is 13.18 vs. the industry median of 11.41, Y.S.P. Southeast Asia Holding Bhd has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Drug Manufacturers company?
The median ROC (Joel Greenblatt) % among Drug Manufacturers companies is 11.41, based on 982 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Y.S.P. Southeast Asia Holding Bhd's current ROC (Joel Greenblatt) % of 18.50% is 62.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Y.S.P. Southeast Asia Holding Bhd and its competitors. For the Drug Manufacturers industry, the median ROC (Joel Greenblatt) % is 11.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Y.S.P. Southeast Asia Holding Bhd's current ROC (Joel Greenblatt) % is 18.50%, which is 40% above median its own 10-year median of 13.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Y.S.P. Southeast Asia Holding Bhd stock overvalued right now?
Based on GuruFocus' analysis, Y.S.P. Southeast Asia Holding Bhd (XKLS:7178) is currently considered Modestly Undervalued. The stock's GF Value™ is RM2.41, compared to a current price of RM2.08 — trading 13.7% below its estimated fair value. The current ROC (Joel Greenblatt) % is 18.50%, which is 40% above median its 10-year median of 13.18 and 62.2% above the Drug Manufacturers industry median of 11.41. Y.S.P. Southeast Asia Holding Bhd's overall GF Score™ is 75/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Y.S.P. Southeast Asia Holding Bhd (XKLS:7178), the current ROC (Joel Greenblatt) % is 18.50% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Y.S.P. Southeast Asia Holding Bhd (XKLS:7178) Overvalued in 2026?
Based on GuruFocus' analysis, Y.S.P. Southeast Asia Holding Bhd stock appears to be undervalued.
The current stock price of RM2.08 is trading 13.7% below its estimated GF Value™ of RM2.41.
GuruFocus considers Y.S.P. Southeast Asia Holding Bhd to be Modestly Undervalued.
Key valuation signals for XKLS:7178:
ROC (Joel Greenblatt) %: 18.50% (40% above median its 10-year median of 13.18)
GF Value™: RM2.41 vs. price of RM2.08 (13.7% below fair value)
Industry Position: 62.2% above the Drug Manufacturers median (#475 of 982)
No single metric tells the full story. See the XKLS:7178 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Y.S.P. Southeast Asia Holding Bhd Business Description
Y.S.P. Southeast Asia Holding Bhd is an investment company, that engages in the pharmaceutical business, and provision of management services. The company operates through the following segments: Trading, Manufacturing, and Investment Holding. The Trading segment imports, exports, and trading in various kinds of pharmaceutical products, and traditional herbal and veterinary products. The Manufacturing segment manufactures pharmaceutical products. The Investment Holding segment focuses on investment holding activity. The firm's majority of revenue comes from the Manufacturing segment. The majority of revenue is derived from Malaysia.
75GF Score
Get the complete analysis for XKLS:7178
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKLS:7178 has been successfully added to your 
